Table 3.
Anti-AXL monoclonal antibodies and nucleotide aptamers currently being investigated
| Name | Type | Target | Indications | Phase of clinical trials |
|---|---|---|---|---|
| YW327.6S2 | Monoclonal antibody | AXL | NSCLC, breast cancer | Preclinical |
| D9 | Monoclonal antibody | AXL | Pancreatic cancer | Preclinical |
| E8 | Monoclonal antibody | AXL | Pancreatic cancer | Preclinical |
| MAb173 | Monoclonal antibody | AXL | Kaposi sarcoma | Preclinical |
| AXL-107-MMAE | Antibody-drug conjugate | AXL | Melanoma | Preclinical |
| 64Cu-anti-hAXL | 64Cu-labeled anti-human antibody | AXL | Breast cancer | Preclinical |
| Axl specific CAR and SynNotch receptor | CAR and synNotch receptors | AXL | Leukemia | Preclinical |
| GL21.T | RNA nucleotide aptamer | AXL | NSCLC | Preclinical |
| GL21.T/miR-34c chimera | conjugate of miR-34c and GL21.T | AXL | NSCLC | Preclinical |
| DNA AXL-APTAMER | DNA nucleotide aptamer | AXL | Ovarian cancer | Preclinical |
Abbreviation: NSCLC non-small cell lung cancer